Screening for and treating hepatitis B virus in patients with HIV infection

Clinical Infectious Diseases

Volumn 45, Issue 5, 2007, Pages 633-636

  Tillmann, Hans L ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; NOTE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MASS SCREENING; PRACTICE GUIDELINES;

EID: 34548275017     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520753     Document Type: Note

References (39)

1. Müller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. EUROHEP consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. J Hepatol 1994; 21:1140-3.
2. Krüger M, Tillmann HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2:253-62.
3. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63:393-6.
4. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419-27.
5. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13:349-60.
6. Iwalokun BA, Hodonu SO, Olaleye BM, Olabisi OA. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria. Afr J Med Med Sci 2006; 35:337-43.
7. Bodsworth NJ, Cooper D, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163:1138-40.
8. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007; 21:771-4.
9. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006; 44:536-9.
10. Sheng WH, Hung CC, Kao JH, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44:988-95.
11. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J Hepatol 1997; 27:18-24.
12. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
13. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-45.
14. Sherman KE. New paradigms in the management of hepatitis C virus co-infections. Nat Clin Pract Gastroenterol Hepatol 2007; 4(Suppl 1):S10-6.
15. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43:904-10 (erratum: Clin Infect Dis 2006;43:1376).
16. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis b virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624-32 (in this issue).
17. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-5.
18. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-31.
19. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007; 46:734-42.
20. Gaglio PJ, Sterling R, Daniels E, Tedaldi E, Terry Beirn Community Programs for Clinical Research on AIDS Hepatitis Working Group. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy. Clin Infect Dis 2007; 45:618-23 (in this issue).
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39.
22. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
23. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
24. Cornberg M, Protzer U, Dollinger MM, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-register 021/011 [in German]. Z Gastroenterol 2007; 45:525-74.
25. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-24.
26. Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 2007; 44:996-1000.
27. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472-89.
28. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B: 13-14 September, 2002 Geneva, Switzerland: consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-25
29. Piroth L, Sene D, Pol S, et al. Epidemiology, diagnosis, and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 Study). AIDS 2007; 21:1323-31.
30. Pierone G Jr, Mieras J, Bulgin-Coleman D, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 2006; 7:237-45.
31. Cameron DW, da Silva B, Arribas J, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC [abstract 44]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retroviruses and Human Health, 2007.
32. Wursthorn K, Buggisch P, Lütgehetmann M, Zollner B, Petersen J. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006; 11:647-52
33. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13:627-31.
34. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000-5.
35. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43:556-62.
36. Da Silva LC, Madruga CL, Carrilho FJ, et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis: lack of correlation with hepatitis C and D virus superinfection. J Gastroenterol 1996; 31:696-701.
37. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187-92.
38. Nunez M, Ramos B, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 2006; 22:842-8.
39. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.